Food and Drug Administration policy on chronic wound healing products
2026 · 3rd Quarter (July 1 - Sep 30)
ORGANOGENESIS INC.
Filed by ARENTFOX SCHIFF LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- ARENTFOX SCHIFF LLP
- Client
- ORGANOGENESIS INC.
- Filing UUID
- 9c81f70c-dd21-4008-bdf4-c95e3805d2ca
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Medicare reimbursement policy for chronic wound healing products, including Local Coverage Determinations and Discarded Products policy Physician Fee Schedule regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027) Hospital Outpatient Prospective Payment System regulations regarding reimbursement for chronic wound healing products (CY2026 and CY2027)
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.